Continuing with our "Research Focus: Breast Cancer" theme, this week’s Product Spotlight highlights additional products that may be useful in Breast Cancer research. Last issue's Product Spotlight had more proteins than peptides featured. So this time we are inverting the ratio, and therefore predominately highlighting peptides.
First up are three TAPI (TNF-Alpha Protease Inhibitor) products, and all of these are Matrix Metalloproteinases (MMPs) inhibitors. MMPs are involved in the degradation of the extracellular matrix (ECM) and are thought to provide a pathway for invasion by cancerous tumor cells.
Bombesin, originally isolated in the skin of the frog bombina, is a tumor marker for carcinomas, being present in 68% of bronchial carcinoids, 65% pulmonary neuroendocrine carcinomas, 62% of neuroendocrine carcinomas of the skin.1 It is thought to act like a growth factor in tumor tissue.2
Somatostatin-14, or somatotropin release-inhibiting factor (SRIF), inhibits growth hormone and has several active octapeptide derivatives. One of those, Octreotide, is a somatostatin analog and plays a role in downregulating MMP-2 and may hinder tumor invasion and metastasis.
We invite you to take a look at another cancer spotlight: "LH-RH and other Neurohormones for Cancer Research" and a past PepTalk, “Target: Cancer. Mission: Search & Destroy” for additional, related products.
- G. Chejfec, I. Lee, W.H. Warren, V.E. Gould, Peptides, 6 Suppl 3, 107 (1985).
- D.W. Kufe et al., editors, Holland-Frei Cancer Medicine, 6th ed, Hamilton (ON): BC Decker; 2003.
- C.-Z Huang et al.,Cell Physiol Biochem, 47, 2340 (2018).